Canada markets close in 4 hours 3 minutes

PFE Aug 2024 27.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.2600+0.1900 (+17.76%)
As of 11:19AM EDT. Market open.
Full screen
Previous Close1.0700
Open1.1600
Bid1.2500
Ask1.2800
Strike27.00
Expire Date2024-08-16
Day's Range0.9400 - 1.2700
Contract RangeN/A
Volume476
Open Interest11.98k
  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts

    NEW YORK, June 18, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2024 Performance Report, to be issued that morning.

  • Zacks

    Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

    Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.

  • Reuters

    Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit

    The U.S. state of Kansas on Monday sued Pfizer, accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness. In a lawsuit filed in the District Court of Thomas County, the state said the New York-based drugmaker's alleged false statements violated the Kansas Consumer Protection Act. "Pfizer made multiple misleading statements to deceive the public about its vaccine at a time when Americans needed the truth," Kansas Attorney General Kris Kobach, a Republican, said in a statement.